Tagestherapiezentrum am ITM & III. Medizinische Klinik, Universitätsmedizin Mannheim
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hofheinz, Ralf
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed
3
430
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
07/24
07/24
NCT04375605: Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Active, not recruiting
3
342
Europe
5-Fluorouracil, Calcium folinate, Folinic Acid, Oxaliplatin, Docetaxel, Radiation, Oxaliplatin during radiotherapy, 5-Fluorouracil during radiotherapy
Universitätsmedizin Mannheim, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Deutsche Krebshilfe e.V., Bonn (Germany)
Gastroesophageal Junction Adenocarcinoma
12/25
12/25
NCT04495088: Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Recruiting
3
818
Europe
mFOLFOX (neoadjuvant), Folinic acid, Oxaliplatin, 5-FU, XELOX (neoadjuvant), Capecitabine, Oxaliplatin, mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), Capecitabine, infusional 5-FU/FA "AIO" regimen (adjuvant), 5-FU, Folinic acid, infusional 5-FU/FA "de Gramont" (adjuvant)
Ralf Hofheinz, Deutsche Krebshilfe e.V., Bonn (Germany), Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, German Rectal Cancer Study Group
Rectal Cancer
08/30
08/30
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Completed
2
124
Europe
Aflibercept + mLV5FU2, mFOLFOX7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi
Colorectal Cancer
02/24
02/24
NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Active, not recruiting
1/2
56
Europe
Sacituzumab govitecan, Trodelvy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences
Esophagogastric Adenocarcinoma
02/27
03/27
PARAGON, NCT04119362: Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer

Completed
N/A
469
Europe
Quality of live questionnaires, Optional translational project
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Celgene
Pancreatic Adenocarcinoma
06/23
06/23

Download Options